AU2022271790A1 - Dry powder formulations of tacrolimus for administration by inhalation once daily (qd) - Google Patents

Dry powder formulations of tacrolimus for administration by inhalation once daily (qd) Download PDF

Info

Publication number
AU2022271790A1
AU2022271790A1 AU2022271790A AU2022271790A AU2022271790A1 AU 2022271790 A1 AU2022271790 A1 AU 2022271790A1 AU 2022271790 A AU2022271790 A AU 2022271790A AU 2022271790 A AU2022271790 A AU 2022271790A AU 2022271790 A1 AU2022271790 A1 AU 2022271790A1
Authority
AU
Australia
Prior art keywords
tacrolimus
dose
patient
composition
inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022271790A
Other languages
English (en)
Inventor
Dale J. Christensen
Christopher S. Crean
John J. Koleng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canvas Pharmaceuticals Inc
Original Assignee
TFF Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TFF Pharmaceuticals Inc filed Critical TFF Pharmaceuticals Inc
Publication of AU2022271790A1 publication Critical patent/AU2022271790A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022271790A 2021-05-12 2022-05-12 Dry powder formulations of tacrolimus for administration by inhalation once daily (qd) Pending AU2022271790A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187774P 2021-05-12 2021-05-12
US63/187,774 2021-05-12
PCT/US2022/028972 WO2022241105A1 (en) 2021-05-12 2022-05-12 Dry powder formulations of tacrolimus for administration by inhalation once daily (qd)

Publications (1)

Publication Number Publication Date
AU2022271790A1 true AU2022271790A1 (en) 2023-11-23

Family

ID=81928015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022271790A Pending AU2022271790A1 (en) 2021-05-12 2022-05-12 Dry powder formulations of tacrolimus for administration by inhalation once daily (qd)

Country Status (7)

Country Link
US (1) US20220362222A1 (https=)
EP (1) EP4337173A1 (https=)
JP (1) JP2024520912A (https=)
CN (1) CN117750945A (https=)
AU (1) AU2022271790A1 (https=)
CA (1) CA3219943A1 (https=)
WO (1) WO2022241105A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118948810A (zh) * 2024-07-26 2024-11-15 四川大学 一种吸入式的mPEG-PLGA/FK506载药纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
AU2009214443B2 (en) 2008-02-13 2013-10-10 Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration

Also Published As

Publication number Publication date
EP4337173A1 (en) 2024-03-20
WO2022241105A1 (en) 2022-11-17
US20220362222A1 (en) 2022-11-17
CA3219943A1 (en) 2022-11-17
JP2024520912A (ja) 2024-05-27
CN117750945A (zh) 2024-03-22

Similar Documents

Publication Publication Date Title
US12023342B2 (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2020201557B2 (en) Aerosol pirfenidone and pyridone analog compounds
AU2018286571B2 (en) Liquid inhalation formulation comprising RPL554
AU2016213708B2 (en) Aerosol pirfenidone and pyridine analog compounds and uses thereof
US6080762A (en) Pulmonary and nasal delivery of raloxifene
RU2389477C2 (ru) Способы лечения эндобронхиальных заболеваний
US20080057129A1 (en) Drug microparticles
JP2019519489A (ja) 肺高血圧症を治療するための乾燥粉末トレプロスチニル
EP2600830A2 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
US20220362222A1 (en) Once daily formulations of tacrolimus
CN120265283A (zh) (-)-表没食子儿茶素没食子酸酯类化合物的应用
JP2013502579A (ja) リボフラビンベースのエアロゾル及び臨床試験におけるプラセボとしての使用
JP2024506840A (ja) 化学ガス曝露を処置する方法
KR20230005937A (ko) 바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법
CN116916889A (zh) 用于肺高压领域的吸入式伊马替尼
CN114144195A (zh) 血管活性肠肽(vip)用于治疗药源性肺炎的用途
HK40070179A (en) Vasoactive intestinal peptide (vip) for use in the treatment of drug-induced pneumonitis
WO2026061535A1 (zh) 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途以及肺动脉高压的治疗方法
CA3204080A1 (en) Compositions, devices, and methods for treating respiratory disorders
US20220054509A1 (en) Methods of treatment for disease from coronavirus exposure
CN114129546A (zh) 一种吸入用药物组合物
MXPA00009704A (en) Pulmonary and nasal delivery of raloxifene